Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs SpaceX (SPCX) Price & Performance

GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.

The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.

SpaceX (SPCX) trades at $156.54, down 4.21% amid broader market weakness despite recent operational successes. Technical indicators show a bullish trend with strong institutional buying support. The company maintains robust revenue growth projections ($23B for 2026) but faces profitability challenges with negative net margins (-35.66%) and elevated valuations (P/S 72.26). Recent news highlights Starlink's expansion into wireless markets while geopolitical tensions create operational complexities.

Long-term growth prospects remain compelling given SpaceX's dominant market position and Starlink expansion, though current valuations require substantial future execution. Key risks include execution on massive capital expenditures, competitive pressures in satellite communications, and geopolitical sensitivities. Analyst consensus remains strongly bullish with a $211.43 price target representing 35% upside potential from current levels.